J. Wildhaber (Fribourg, Switzerland), A. Zacharasiewicz (HinterbrüHl, Austria)
Passive smoking and the airways reaction to inhaled corticosteroid therapy in children with asthma
S. Radic, Z. Zivkovic, S. Smiljanic, M. Micic-Stanojevic, S. Cerovic, N. Erdeljan, J. Jocic-Stojanovic (Belgrade, Serbia And Montenegro)
|   |
Safety of formoterol in children and adolescents: experience from asthma clinical trials
J. Price, F. Radner, C. Hultquist, B. Lindberg (London, United Kingdom; Lund, Malmo, Sweden)
| |
Characteristics of clinical and objective measures of asthma control in asthmatic children
M. Barreto, R. Zambardi, C. Olita, M. Montesano, S. Barberi, S. Martella, L. Principessa, M. P. Villa (Rome, Italy)
| |
Effect of inhaled fluticasone poprionate and repeated short courses of oral corticosteroid on bone turnover in asthmatic children
A. M. Abd Al-Aziz, A. A. Abou El-Ezz, M. A. M. Awad, E. A. El Ghoroury, N. S. Hasan (Cairo, Egypt)
| |
Superior efficacy of the salmeterol/fluticasone 50/100 mcg combination compared to fluticasone 200 mcg in children with uncontrolled asthma – the VIAPAED trial
M. Gappa, W. Zachgo, A. von Berg, W. Kamin, C. Stern-Straeter (Hannover, Geesthacht, Wesel, Mainz, Muenchen, Germany)
| |
Impact of interactive asthma workshop on asthma childhood management of Belgian pediatricians
K. Desager, G. de Bilderling, A. Malfroot, C. Mossay (Antwerp, Yvoir, Brussels, Liege, Belgium)
| |
Does the provision of a written action plan in the emergency department (ED) improve adherence to physicians‘ recommendations and asthma control in children with acute asthma? A randomized controlled trial
F. Ducharme, R. Zemek, D. Chalut, D. McGillivray, F. Noya, S. Resendes, L. Meng, L. Khomenko, R. Rouleau, X. Zhang (Montreal, QC, Ottawa, ON, Canada)
| |
Effect of addition of salmeterol vs doubling the dose of fluticasone propionate on specific airway resistance in children with asthma
C. Murray, A. Custovic, L. Lowe, S. Aldington, M. Williams, R. Beasley, A. Woodcock (Manchester, United Kingdom; Wellington, New Zealand)
| |
Agreement between asthma control measures in identifying adolescents with uncontrolled asthma
T. Beerthuizen, N. Rikkers-Mutsaerts, A. E. Winters, H. F. van Stel, V. van der Meer, K. F. Rabe, J. K. Sont (Leiden, Netherlands)
| |
The use of omalizumab in the management of severe chronic paediatric asthma
S. Moss, A. Kirk, M. McKean, C. O‘Brien, D. Spencer (Newcastle upon Tyne, United Kingdom)
| |
Asthma quality of life as an assessment tool of asthma severity and treatment effectiveness
M. Kherkheulidze, N. Kavlashvili, E. Kandelaki, N. Adamia, M. Lominadze, S. Broladze (Tbilisi, Georgia)
| |
A randomized controlled study of omalizumab in children with moderate-to-severe persistent allergic asthma
M. Kulus, T. Bridges, A. Fowler-Taylor, M. Blogg, P. Jimenez (Warsaw, Poland; Albany, East Hanover, United States Of America; Horsham, United Kingdom)
| |
Exploring the relationship in children between guideline-defined asthma control, physical activity and BMI
A. Grover, A. P. Fitzgearld, M. Ní Chróinin (Cork, Ireland)
| |
Children with asthma on ICS, treated in general practice or hospital based; are there differences in characteristics?
M. Kuethe, A. Vaessen-Verberne, A. Poppelaars, P. Bindels, W. van Aalderen (RL Breda, Breda, Amsterdam Zuidoost, Netherlands)
| |
Variation of regular maintenance therapy with budesonide/formoterol of children with asthma
N. Geppe, A. Denisova, N. Sokolova, F. Kirdakov (Moscow, Russian Federation)
| |
Evaluation of a diagnostic–therapeutic pathway on GINA guidelines between specialist and primary care physicians. Study and result at 1 year in children with asthma
S. Guarnaccia, M. Chiarini, A. Gaffurini, A. Lombardi, E. D‘Agata, E. Belotti, L. D. Notarangelo, A. Plebani, R. Spiazzi (Brescia, Italy; Boston, MA, United States Of America)
| |